Pulmonx (LUNG) Receivables (2019 - 2025)

Pulmonx (LUNG) has 7 years of Receivables data on file, last reported at $12.1 million in Q4 2025.

• On a quarterly basis, Receivables fell 7.99% year-over-year to $12.1 million in Q4 2025; TTM through Dec 2025 was $12.1 million, a 7.99% decrease from a year earlier, with the FY2025 full-year figure at $12.1 million, down 7.99% from the prior year.
• Receivables for Q4 2025 stood at $12.1 million, down from $13.8 million in the prior quarter.
• Over the last five years, Receivables for LUNG reached as high as $15.9 million in Q2 2025 and fell as low as $5.1 million in Q1 2021.
• Historically, Receivables has averaged $9.9 million across 5 years, with a median of $9.5 million in 2023.
• Across the five-year window, Receivables jumped 55.2% in 2021 and retreated 7.99% in 2025, its largest moves.
• Year by year, Receivables stood at $6.6 million in 2021, then surged by 32.23% to $8.7 million in 2022, then soared by 39.51% to $12.1 million in 2023, then advanced by 8.38% to $13.1 million in 2024, then dropped by 7.99% to $12.1 million in 2025.
• Per Business Quant data, the three most recent Receivables figures were $12.1 million in Q4 2025, $13.8 million in Q3 2025, and $15.9 million in Q2 2025.